Expansion designed to further support growing customer demand for cGMP clinical and commercial biologics production
SEATTLE, July 31, 2012 /PRNewswire/ -- CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, today announced the acquisition of XOMA Corporation's (Nasdaq: XOMA), large-scale manufacturing operations and affiliated assets located in Berkeley, California. Financial terms of the transaction were not disclosed.
"We are very pleased to expand our clinical and commercial manufacturing operations to one of largest and most robust biotechnology clusters in the world," said Claes Glassell, Chief Executive Officer of CMC Biologics. "Establishing a facility in the Bay Area complements our existing facilities located in Bothell, Washington and in Copenhagen Denmark, and supports our continued growth and addresses the growing demand of our customers for cGMP clinical and commercial production of biopharmaceuticals."
The fully functional 31,000 square foot facility is a completely equipped biological manufacturing operation, including three 2750L stainless steel bioreactors and two purification suites, as well as warehouse and office space. CMC Biologics expects to begin offering contract manufacturing services from this location immediately following the close of the transaction.
In June, CMC Biologics received Certificate of Good Manufacturing Practice (GMP) Compliance for commercial manufacturing issued by the Medicines and Healthcare products Regulatory Agency (MHRA). CMC Biologics' commitment to compliance and high quality systems resulted in the success of this important regulatory milestone and demonstrates excellence in the Company's manufacturing, process, and quality systems.
About CMC Biologics
CMC Biologics is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world, from its facilities in Europe and the USA. The company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production. The company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. CMC Biologics is located in Copenhagen, Denmark, and Seattle, Washington. More detailed information can be found at www.cmcbiologics.com.
SOURCE CMC Biologics